IBO (Impact BioMedical) Total Enterprise Value

Impact BioMedical Inc (IBO) relies on American laboratories, outsourcing the production of biomedical devices to external contractors. The price action associated with the 33.57 metric links this model to an investment cycle of development that remains independent of macroeconomic factors. Meanwhile, management is focusing on patent protection and preclinical trials, where success depends on future licensing deals and long-term shareholder confidence.

When constructing a defensive portfolio, fundamental screening requires an assessment of the enterprise value, calculated as the sum of market capitalization and net debt. For Impact BioMedical Inc (IBO), this metric reflects the actual acquisition price of the holding, accounting for the value of its intellectual property in the biodefense sector, which is clearly demonstrated by the enterprise value price action.